Savara (SVRA) has drawn investor interest after recent share price moves, with the stock last closing at $5.41. The clinical stage biopharmaceutical company focuses on rare respiratory diseases, including autoimmune pulmonary alveolar proteinosis.

Recent trading puts Savara’s 1 day share price return at 1.5%, while the 30 day share price return is down 13.0%. Even with this pullback, the 1 year total shareholder return of 100.4% and 5 year total shareholder return of about 3.4x indicate that momentum has been strong over longer periods.

If you are comparing Savara with other growth ideas in healthcare, it can be useful to scan a focused group of AI driven opportunities through the 41 healthcare AI stocks.

Savara’s long term share price record and recent pullback paint a mixed picture of success and fresh uncertainty. The company’s science may be strong, but is the stock’s current US$5.41 price a fair deal today?

Price to Book Valuation: Is Savara’s Premium Justified?

On a simple valuation check, Savara trades at a clear premium to peers. The stock’s price to book ratio of 7.8x sits well above both the US Biotechs industry average of 2.4x and a peer group average of 4.4x.

The P/B multiple compares the market value of Savara to its book value, which for a clinical stage biopharmaceutical company is often driven by cash, research assets, and accumulated losses rather than established earnings. A higher P/B can signal that investors are placing a higher value on future potential relative to the underlying net assets.

For readers, the key implication is that the market is already pricing in a strong outlook for Savara’s pipeline and expected earnings growth rather than current fundamentals. Analysts are forecasting annual revenue growth of 56.7% and earnings growth of 65.56%, and the company is expected to move from losses to profitability within the next 3 years. That growth profile helps explain why the P/B multiple is materially above industry levels, even though there is insufficient data to run the SWS DCF model for a fair value cross check at this stage.

Compared with the broader US Biotechs industry average P/B of 2.4x and a peer average of 4.4x, Savara’s 7.8x multiple stands out as expensive in relative terms. The current valuation leaves less room for disappointment if forecasts or clinical milestones do not play out as expected, and it suggests investors should pay close attention to how future results line up with these growth assumptions.

Result: Price-to-book of 7.8x (OVERVALUED)

However, the Savara story can quickly change if clinical trial outcomes disappoint or if funding needs result in shareholder dilution at less favorable prices.

Next Steps

Given this mix of optimism and concern around Savara, it makes sense to review the data quickly and decide where you stand. To weigh both sides of the story in one place, check out the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Savara?

If you like the potential in Savara but want a broader watchlist, now is the time to line up a few more ideas that fit your style.

• Target rock solid businesses first by checking companies in the solid balance sheet and fundamentals stocks screener (49 results) so you can focus on those with healthier foundations.
• Pursue mispriced opportunities using the 52 high quality undervalued stocks to spot stocks where quality and price may be out of sync.
• Secure potential income streams by reviewing the 7 dividend fortresses and see which companies could complement a long term dividend plan.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.